Business Wire

IL-NEXTSENSE

3.12.2021 16:02:13 CET | Business Wire | Press release

Share
NextSense Emerges to Unlock Brain Health with Key Partners UCB, Heraeus, UC San Diego, and Emory University

NextSense, the foundation of brain health, came out of stealth with an announcement made from the AES (American Epilepsy Society) Annual Meeting in Chicago, where NextSense and its partners are presenting the results of their research on seizure detection to peers in academia and industry for the first time.

NextSense unlocks brain health with real world data insights and practical, scientific wisdom for daily living. Traditional brain health monitoring technology like EEG machines and polysomnograms are too bulky for home use, requiring patients to stay overnight at hospitals or sleep study clinics for observation. The high cost of care and lack of comfort of these devices makes long-term and continuous monitoring nearly impossible. Not only are these data based on a single timeframe, they observe what is anything but an ordinary night’s sleep. And for anyone living with epilepsy, the unpredictability of seizures makes direct observation and high-quality data-gathering exceedingly rare.

The NextSense platform starts with longitudinal EEG data collected at the point of experience with biosensing earbuds that can be worn comfortably at night and as-needed throughout the day. The company envisions combining that data with environmental and behavioral patterns collected from smart devices and timely analysis from its team of neuroscientists to help doctors identify triggers, diagnose certain conditions and tailor treatment and medication recommendations in real-time.

At the AES Annual Meeting, NextSense detailed for the first time its key relationship with biopharma partner UCB. The company also revealed research and IP agreements with both Heraeus and UC San Diego, as well as a multi-dimensional collaboration with researchers at Emory University.

“We believe that technologies that enable earlier detection of seizures and improve the coordination of care for people living with epilepsy complement UCB’s strong heritage in epilepsy and portfolio of medicines,” said Colin Lake, Vice President of Digital Business Transformation for Neurology at UCB. “Being able to access meaningful data that NextSense can provide will allow us to capture insights and solve complex disease questions that will help epilepsy patients on their care journey achieve better outcomes.”

Each pharma and biotech company has partnered with NextSense to study how neurologists can better calibrate and manage treatment plans for epilepsy, sleep, and potentially other CNS disorders, using the company’s platform.

Emory University’s Brain Health Center, led by world-renowned physician-scientist Allan Levey, is the site of multiple NextSense studies and its first two clinical trials.

"We're excited for what this partnership means for both NextSense and Emory Brain Health," said Allan Levey, Founding Director of Goizueta Institute at Emory Brain Health. "Our work alongside Emory's Department of Biomedical Informatics signifies a notable step forward toward chronic ambulatory monitoring of brain physiology via EEG. With their earbuds allowing access for monitoring data over much longer periods of time, the initial findings and foundational work are very promising and showing how their efforts and technology has significant potential to revolutionize the approach to diagnosing and treating many neurological disorders in the future."

“We’ve assembled a dream team of collaborators,” said Jonathan Berent, Founder and CEO of NextSense. “It is a personal and professional thrill to partner with these innovators at the very top of their field. Our partners have worked with us shoulder-to-shoulder to methodically pursue what many people said was impossible. We are beyond excited to begin to show the world what we have achieved, starting with the scientific community at AES.”

NextSense is continuing to enroll participants in clinical trials focused on epilepsy and sleep. Eventually, the company hopes to leverage the long-term data collected to help establish biomarkers for brain health.

“Whether someone is living with epilepsy, struggling to stay alert, or seeking an elusive diagnosis for a neurological condition, we’re offering hope,“ said Jen Dwyer, Medical Director of NextSense. “We see our members from every angle, and we understand their unique pain points. We’re working towards a world where those who suffer from these conditions don’t have to choose between comfort and accuracy. And we’re just getting started.”

About NextSense, Inc.

NextSense is the foundation of a healthy brain.

We unlock brain health with real-world data insights and practical, scientific wisdom for daily living. Whether you are struggling to stay alert, living with something like epilepsy, seeking an elusive diagnosis for a neurological condition, we can help.

We are a passionate team of neuroscientists and venture operators on a mission to catalyze brain health in both science and culture.

To learn more, please visit: www.nextsense.io

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 19:09:00 CET | Press release

PriceRunner v. Google: Sweden’s Largest-Ever Civil Damages Claim Reaches Decision Stage; Klarna Provides Investor Update Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results whi

INRIX Announces New Generation of AI Traffic Products: Helping to Improve Safety, Reduce Congestion, and Enhance Mobility Operations24.2.2026 16:49:00 CET | Press release

New generative AI capabilities, enhanced incident detection, and expanded customer deployments mark a major evolution of the INRIX Traffic product family INRIX, a global leader in transportation data and analytics, today announced a major expansion of its Trafficfamily of products, delivering innovativeAI-driven capabilities to help transportation agencies and logistics organizations move from reactive traffic management to proactive, safety-focused and efficient operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224267928/en/ INRIX introduces expanded automation, generative AI capabilities, enhanced incident detection, and continuous analytics. Over twenty years ago, INRIX commercialized the first system to use GPS data to create real-time traffic information. In 2019, INRIX launched AI Traffic – the world's first traffic platform to leverage deep learning models and AI to improve the quality and analysis globall

Check Point and ControlPlane Partner to Help Enterprises Securely Scale AI and Accelerate Agentic Innovation24.2.2026 15:30:00 CET | Press release

ControlPlane, a specialist AI Security and DevSecOps consultancy, and Check Point Software Technologies Ltd., a pioneer and global leader in cyber security solutions, today announced a strategic collaboration to help enterprises securely adopt Large Language Models (LLMs) and agentic AI systems at scale. The partnership delivers a comprehensive, regulator-ready security framework designed to reduce risk, protect sensitive data, and enable organizations to move confidently from AI experimentation to production deployment. By combining Check Point’s AI-native threat prevention platform with ControlPlane’s deep expertise in cloud native architectures and DevSecOps, enterprises can operationalize AI securely without slowing innovation. As organizations advance AI initiatives beyond pilots, they face a growing “AI readiness gap.” Emerging threats such as prompt injection, unauthorized access, data leakage, and model misuse introduce risks that traditional security controls were not built to

Clinilabs Establishes EU Headquarters in Basel, Strengthening European Clinical Operations Under New Regional Leadership24.2.2026 15:00:00 CET | Press release

Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced the expansion of its European operations, including the establishment of its European Union headquarters at Switzerland Innovation Park Basel Area, and the appointment of Dr. Anne-Marie Nagy as executive vice president and head of Clinilabs Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224669284/en/ Dr. Anne-Marie Nagy appointed as Executive Vice President and Head of Clinilabs Europe Switzerland Innovation Park Basel Area is part of Switzerland’s national innovation network and located within the Basel region’s globally recognized life sciences cluster, bringing together biopharma companies, research institutions, and clinical innovation leaders. “Europe is a critical pillar of Clinilabs’ long-term growth strategy,” said Gary K. Zammit, Ph.D., president and chie

Yubico Unveils “YubiNation Partners”: A New Era of Global Channel Partnership to Secure Digital Identities in the Age of AI24.2.2026 15:00:00 CET | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), a modern cybersecurity company and creator of the most secure passkeys, today announced the launch of YubiNation Partners, a new global Channel program designed to unite a community of security experts. In the face of growing AI-driven cyber threats, the program enables partners to become trusted advisors and cultivate a safer digital world for their customers, making identities private and secure. As the average cost of a corporate security breach climbs to $4.4 million*, with phishing remaining a primary attack vector, the industry can no longer rely on passwords alone. In fact, a 2026 Total Economic Impact study from Forrester Consulting commissioned by Yubico, found that by replacing traditional multi-factor authentication (MFA) and one-time passwords (OTP) with YubiKeys, customers achieved a 265% return on investment (ROI). This effectively eliminated phishing and credential-theft risks, reducing an organization’s risk exposure to breach costs fr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye